Crispr Stem & Therapeutics (CST)

Company Overview

Snapshot

Founded in May 2018 by Dr. Dalia El-Ani, Crispr Stem & Therapeutics (CST) operates with 1–10 employees. The company has secured $100,000 across one funding round and received recognition from the Israeli Innovation Authority and the European Commission with two Seals of Excellence.

Business overview

Crispr Stem & Therapeutics (CST) is a Health Tech & Life Sciences company focused on developing gene and cell therapy solutions for acute myocardial ischemia and chronic heart failure. The company's core technology utilizes a patented CRISPR-based stem cell protocol to genetically modify a patient's own stem cells, which are then implanted to restrict heart damage. CST operates within the Pharma & Medical Biotechnology sector, specifically in Drugs Discovery & Development, targeting healthcare providers and the biotechnology segment of life sciences.

Company Intelligence Q&A

What is Crispr Stem & Therapeutics' primary focus?

Crispr Stem & Therapeutics (CST) is developing gene and cell therapy for acute myocardial ischemia and chronic heart failure, aiming to restrict damage to the heart following these conditions.

Who founded Crispr Stem & Therapeutics?

Crispr Stem & Therapeutics (CST) was founded by Dr. Dalia El-Ani in May 2018.

What is the core technology of Crispr Stem & Therapeutics?

The company's technology uses CRISPR to genetically modify a patient's own stem cells, which are then treated by Crispr Stem & Therapeutics' protocol and implanted to reduce heart damage.

Has Crispr Stem & Therapeutics received any significant recognition?

Crispr Stem & Therapeutics (CST) received recognition from the Israeli Innovation Authority and the European Commission with two Seals of Excellence.

What was Crispr Stem & Therapeutics' most recent funding event?

In January 2020, Crispr Stem & Therapeutics (CST) received a grant from the Israel Innovation Authority.